Avidity Partners Management LP lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 18.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 615,000 shares of the biotechnology company’s stock after selling 136,600 shares during the quarter. Blueprint Medicines accounts for approximately 2.1% of Avidity […]
Avidity Partners Management LP decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 615,000 shares of the biotechnology company’s stock after selling 136,600 shares during the quarter. Blueprint Medicines comprises […]
Eagle Asset Management Inc. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 231,396 shares of the biotechnology company’s stock after acquiring an additional 22,279 […]
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Equities researchers at Zacks Research issued their Q2 2024 earnings per share estimates for shares of Blueprint Medicines in a report released on Tuesday, May 14th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will earn ($1.40) per share for the quarter. The consensus estimate […]
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Analysts at Zacks Research issued their Q2 2024 earnings per share estimates for Blueprint Medicines in a report released on Tuesday, May 14th. Zacks Research analyst A. Chakraborty anticipates that the biotechnology company will post earnings of ($1.40) per share for the quarter. The consensus estimate for […]